The Curtis Life Sciences group provides a wide range of legal services to clients in the life sciences sector, including manufacturers, funds and institutions in branded and generic pharmaceuticals, medical devices, biotechnology equipment, clinical systems, nanotechnology, medical software, OTC and prescription drugs and drug packaging.
The range of services provided by the group includes:
- Stock and asset acquisitions and divestitures
- Mergers, equity and debt offerings
- Private placements
- Venture capital financings
- Partnering agreements, including joint ventures and strategic alliances
- Research and development
- Supply and distribution
- Contract manufacturing
The firm’s Life Sciences group regularly advises a wide variety of clients from start-up and early-stage ventures to established Fortune Global 500 corporations. The transactional practice specialises in cross-border deals for US, European and multinational corporations.
Curtis litigators represent pharmaceutical companies in a wide array of civil and regulatory matters, with particular focus on patent (Hatch-Waxman), product liability (including multidistrict litigation), advertising and trademark disputes and international arbitration. The firm has a full-time Ph.D scientific analyst on staff to assist with its life sciences matters.
For more information on life sciences click here.
News from Curtis Mallet-Prevost Colt & Mosle
News from The Lawyer
Briefings from Curtis Mallet-Prevost Colt & Mosle
US copyright and trademark law is now much closer to that of Europe, but key differences remain.
The treatment of intellectual property licenses under US bankruptcy law